» Articles » PMID: 16646070

Time to Clearance of Human Papillomavirus Infection by Type and Human Immunodeficiency Virus Serostatus

Overview
Journal Int J Cancer
Specialty Oncology
Date 2006 Apr 29
PMID 16646070
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

Persistent infection with high-risk human papillomavirus (HPV) is central to cervical carcinogenesis. Certain high-risk types, such as HPV16, may be more persistent than other HPV types, and type-specific HPV persistence may differ by HIV serostatus. This study evaluated the association between HPV type and clearance of HPV infections in 522 HIV-seropositive and 279 HIV-seronegative participants in the HIV Epidemiology Research Study (HERS, United States, 1993-2000). Type-specific HPV infections were detected using MY09/MY11/HMB01-based PCR and 26 HPV type-specific probes. The estimated duration of type-specific infections was measured from the first HPV-positive visit to the first of two consecutive negative visits. Hazard ratios (HRs) and 95% confidence intervals (CIs) for HPV clearance were calculated using Cox models adjusted for study site and risk behavior (sexual or injection drugs). A total of 1,800 HPV infections were detected in 801 women with 4.4 years median follow-up. HRs for clearance of HPV16 and related types versus low-risk HPV types were 0.79 (95% CI: 0.64-0.97) in HIV-positive women and 0.86 (95% CI: 0.59-1.27) in HIV-negative women. HRs for HPV18 versus low-risk types were 0.80 (95% CI: 0.56-1.16) and 0.57 (95% CI: 0.22-1.45) for HIV-positive and -negative women, respectively. HPV types within the high-risk category had low estimated clearance rates relative to low-risk types, but HRs were not substantially modified by HIV serostatus.

Citing Articles

Oncogenic Oral Human Papillomavirus Clearance Patterns over 10 Years.

DSouza G, Tewari S, Troy T, Webster-Cyriaque J, Wiley D, Lahiri C Cancer Epidemiol Biomarkers Prev. 2024; 33(4):516-524.

PMID: 38294704 PMC: 10990780. DOI: 10.1158/1055-9965.EPI-23-1272.


Human papillomavirus in the setting of immunodeficiency: Pathogenesis and the emergence of next-generation therapies to reduce the high associated cancer risk.

Hewavisenti R, Arena J, Ahlenstiel C, Sasson S Front Immunol. 2023; 14:1112513.

PMID: 36960048 PMC: 10027931. DOI: 10.3389/fimmu.2023.1112513.


Risk Analysis Stratification of CIN 2+ Development in a Cohort of Women Living with HIV with Negative Pap Smear and HR-HPV Test during a Long-Term Follow-Up.

Gardella B, Agarossi A, Dominoni M, Pagano I, Del Frati S, Di Giminiani M Vaccines (Basel). 2023; 11(2).

PMID: 36851143 PMC: 9961029. DOI: 10.3390/vaccines11020265.


Alteration of the IFN-Pathway by Human Papillomavirus Proteins: Antiviral Immune Response Evasion Mechanism.

Castro-Munoz L, Rocha-Zavaleta L, Lizano M, Ramirez-Alcantara K, Madrid-Marina V, Manzo-Merino J Biomedicines. 2022; 10(11).

PMID: 36428532 PMC: 9687819. DOI: 10.3390/biomedicines10112965.


Effect of Human Immunodeficiency Virus Infection on Human Papillomavirus Clearance Among Women in Senegal, West Africa.

Li Z, Winer R, Ba S, Sy M, Lin J, Feng Q J Infect Dis. 2022; 227(9):1088-1096.

PMID: 36314598 PMC: 10319963. DOI: 10.1093/infdis/jiac428.